A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia

Tardive Dyskinesia Clinical Trial

— KINECT 3  

Official title:

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02274558
• Other study ID #: NBI-98854-1304
• Status: Completed
• Phase: Phase 3
• First received: October 22, 2014
• Last updated: October 12, 2016
• Start date: October 2014
• Est. completion date: July 2016

Study information

• Verified date: October 2016
• Source: Neurocrine Biosciences
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy, safety, and tolerability of NBI-98854 administered once daily for the treatment of Tardive Dyskinesia (TD) symptoms.

Description:

This is a Phase 3, randomized, double-blind, placebo-controlled, parallel, fixed-dose study to evaluate the efficacy, safety, and tolerability of two doses of NBI-98854 (40 mg and 80 mg) compared to placebo, administered once daily. The study design includes a double-blind, placebo-controlled treatment period for 6 weeks and a double-blind NBI-98854 treatment period for an additional 42 weeks, for a total of 48 weeks of treatment. Final follow-up assessments will be conducted 4 weeks after the last dose of the study drug.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 234
• Est. completion date: July 2016
• Est. primary completion date: September 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

1. Subjects of childbearing potential must agree to use hormonal or two forms of nonhormonal contraception (dual contraception) consistently during the screening, treatment and follow-up periods of the study.

2. Female subjects must not be pregnant.

3. Have one of the following clinical diagnoses for at least 3 months prior to screening: Schizophrenia or Schizoaffective Disorder, or Mood Disorder.

4. Have a clinical diagnosis of neuroleptic-induced TD for at least 3 months prior to screening.

5. Have moderate or severe TD.

6. If using maintenance medication(s) for schizophrenia or schizoaffective disorder, or mood disorder, be on stable doses.

7. Be in good general health.

8. Have adequate hearing, vision, and language skills to perform the procedures specified in the protocol.

9. Have a negative drug screen for amphetamines,barbiturates, benzodiazepines, phencyclidine, cocaine, opiates, or cannabinoids

Exclusion Criteria:

1. Have an active, clinically significant unstable medical condition within 1 month prior to screening.

2. Have a known history of substance dependence, or substance (drug) or alcohol abuse

3. Have a significant risk of suicidal or violent behavior.

4. Have a known history of neuroleptic malignant syndrome.

5. Have a known history of long QT syndrome or cardiac tachy-arrhythmia.

6. Have a cancer diagnosis within 3 years of screening (some exceptions allowed)

7. Have received an investigational drug within 30 days prior to screening or plan to use an investigational drug (other than NBI-98854) during the study.

8. Have a blood loss =550 mL or donated blood within 30 days prior to Baseline.

9. Have an allergy, hypersensitivity, or intolerance to tetrabenazine.

10. Have had previous exposure with NBI-98854 or had previously participated in an NBI-98854 clinical study.

11. Are currently pregnant or breastfeeding.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Dyskinesias
• Movement Disorders
• Tardive Dyskinesia

Intervention

Drug:
• NBI-98854
NBI-98854 40 mg capsules
• Placebo
NBI-98854 placebo capsules

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Neurocrine Biosciences

Countries where clinical trial is conducted

United States,  Canada,  Puerto Rico, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Severity of tardive dyskinesia (TD) symptoms assessed by Abnormal Involuntary Movements Scale (AIMS), change from baseline		Baseline, Week 6	No
Secondary	Clinical Global Impression of Change - TD (CGI-TD)		Week 6	No
Secondary	Tardive Dyskinesia Impact Scale (TDIS)		Week 6	No
Secondary	Patient Global Impression of Change (PGIC)		Week 6	No
Secondary	Percentage of subjects classified as responders based on AIMS dyskinesia total score % change from baseline		Baseline, Week 6	No
Secondary	Percentage of subjects classified as responders based on CGI-TD		Week 6	No